Replies to post #234981 on Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

If Prurisol is almost twice (189%) as effective as methotrexate for treating ulcerative colitis (UC), then Prurisol could be a go to oral treatment for ulcerative colitis (UC).

Efficacy, Safety and Mucosal Healing of Methotrexate in a Large Longitudinal Cohort of Inflammatory Bowel Disease Patients.
Rouiller-Braunschweig C1, Fournier N2, Pittet V2, Dudler J3, Michetti P4.
Author information
1
Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland.
2
Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Lausanne, Switzerland.
3
Service de Rhumatologie, Médecine Physique et Rééducation, Fribourg, Switzerland.
4
Crohn's and Colitis Center, Gastro-entérologie La Source-Beaulieu and Division of Gastroenterology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Abstract
BACKGROUND/AIMS:
Evidence for the effectiveness of methotrexate (MTX) in treating inflammatory bowel disease (IBD) is still incomplete. This study assessed the effectiveness, safety and mucosal healing in IBD patients treated with MTX in the Swiss IBD Cohort.

METHODS:
Efficacy was defined by physician assessment or by CD activity index <150 points for Crohn's disease (CD) or Modified Truelove and Witts activity index <4 points for ulcerative colitis (UC), measured at least after 3 months of MTX therapy. Mucosal healing was evaluated after 3 months or more of therapy.

RESULTS:
MTX was administered to 341 patients (262 CD; 79 UC) out of 2,660 patients. MTX effectiveness was 59.5% (128/215) in CD and 40.0% (24/60) in UC (chi2 = 7.2409, p = 0.007). Among patients on MTX therapy at the time of analysis, remission was obtained in 87.4% (76/87) and 69.2% (9/13) for CD and UC patients respectively. The median duration of MTX therapy was 40 months for CD and 15 months for UC. Occurrence of adverse events was the first reason for treatment discontinuation (39.4% of all cases). The rate of mucosal healing with MTX was 9.5% for CD and 25% for UC patients respectively.

CONCLUSION:
MTX therapy was effective for the induction and maintenance therapy in IBD patients, with only a modest mucosal healing ability.

https://www.ncbi.nlm.nih.gov/pubmed/29065423

Good luck and GOD bless,

George